多西他赛联合表阿霉素治疗晚期三阴乳腺癌临床观察

目的观察多西他赛联合表阿霉素治疗晚期三阴乳腺癌患者的疗效及不良反应。方法 37例三阴乳腺癌患者给予多西他赛75 mg/m2第1天;表阿霉素60 mg/m2,第2天,21 d为1个周期,至少2个周期化疗。结果 37例患者中完全缓解1例,部分缓解16例,稳定9例,进展11例,有效率为45.9%,疾病控制率为70.3%,中位生存时间为10.8个月。治疗的主要不良反应是骨髓抑制。结论晚期三阴乳腺癌患者预后差,采用多西他赛联合表阿霉素方案治疗安全有效,可延长患者生存时间,不良反应可以接受。

Clinical observation of Docetaxel plus Epirubicin in advanced triple negative breast cancer

Objective To observe the curative effect and toxicity of Docetaxel plus Epirubicin in advanced triple negative breast cancer.Methods 37 triple negative breast cancer patient received Docetaxel 75 mg / m2on d1 and Epirubicin 60 mg / m2 on d2 of every 21 days.Every patient was administered at least 2 cycles.Results One patient achieved complete response,16 were partial response,9 were stable disease,11 were progressive disease,the overall response rate was 46%,the middle time of survive was 10.8 month.Conclusion The results of advanced triple negative breast cancer patient is badless.Combined chemotherapy of Docetaxel plus Epirubicin in advanced triple negative breast cancer patient has a manageable toxicity,and was useful and safety,it can prolong the survive time